Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 205
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent...
Psychedelics and Substance Use Disorder: 4000 BCE to Present Day
Psyched Wellness Announces Path to Market for AME-1-derived Products in the...
COMPASS Pathways announces changes in Executive Team
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial...
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with...
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and...
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office...
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...
Editor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity
Load more